The only* fully human selective IL-23 inhibitor built to neutralize IL-23 locally at the cellular source of inflammation^1*

*Based on approved IL-23 inhibitors for active PsA as of October 2023.

Findings are limited to in vitro studies that demonstrated guselkumab’s binding to CD64 in an inflammatory monocyte model. The clinical significance of the findings is not known.

Learn about the TREMFYA^® molecular structure with Dr. Gordon Lam

Dr. Gordon Lam is a paid consultant for Janssen and must present information in accordance with FDA
guidelines. Learn more about Dr. Lam

TREMFYA^® has a unique structure¹

Consistent with the IL-23 class, TREMFYA^® is a monoclonal antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor²

TREMFYA^® is structurally different in the Fc region from other selective IL-23 inhibitors approved in active PsA. Only TREMFYA^® is fully human and able to bind to CD64 with its Fc region at the source of IL-23 production.*

Differences in clinical pharmacology cannot be used to establish differences in efficacy or safety.

TREMFYA^® is the only selective IL-23i with dual binding^1*†

The only selective IL-23 inhibitor built to neutralize IL-23 locally at the cellular source of inflammation¹*

^†TREMFYA^® binds to CD64 at the cellular source of inflammation with its Fc region while also binding to expressed IL-23 via its antigen-binding domain.

Findings are limited to in vitro studies. The clinical significance of the findings is not known.

CD64=FcyRI; Fc=Fragment crystallizable region.

*Based on approved IL-23 inhibitors for active PsA as of October 2023.